Published in Cochrane Database Syst Rev on April 18, 2007
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future. J Oncol (2013) 1.05
AACR Cancer Progress Report 2014. Clin Cancer Res (2014) 1.05
An elevated peripheral blood lymphocyte-to-monocyte ratio predicts favorable response and prognosis in locally advanced breast cancer following neoadjuvant chemotherapy. PLoS One (2014) 1.01
Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer. Br J Cancer (2016) 0.86
Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer. Ann Surg Oncol (2015) 0.86
Prognostic value of DCE-MRI in breast cancer patients undergoing neoadjuvant chemotherapy: a comparison with traditional survival indicators. Eur Radiol (2014) 0.84
Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy. World J Surg Oncol (2014) 0.84
Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer. Br J Cancer (2010) 0.84
Impact of neoadjuvant chemotherapy on immediate breast reconstruction: a meta-analysis. PLoS One (2014) 0.83
Treatment response assessment of breast masses on dynamic contrast-enhanced magnetic resonance scans using fuzzy c-means clustering and level set segmentation. Med Phys (2009) 0.83
Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions. World J Clin Oncol (2014) 0.82
Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors. Drugs R D (2011) 0.82
Review of breast conservation therapy: then and now. ISRN Oncol (2011) 0.82
The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer. Oncol Rev (2017) 0.82
Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast (2015) 0.81
Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. Springerplus (2015) 0.80
Oncoplastic breast surgery: current strategies. Gland Surg (2015) 0.79
Platelet-Lymphocyte Ratio as a Useful Predictor of the Therapeutic Effect of Neoadjuvant Chemotherapy in Breast Cancer. PLoS One (2016) 0.78
Neoadjuvant chemotherapy and short-term morbidity in patients undergoing mastectomy with and without breast reconstruction. JAMA Surg (2014) 0.78
Magnetic resonance imaging shrinkage patterns following neoadjuvant chemotherapy for breast carcinomas with an emphasis on the radiopathological correlations. Mol Clin Oncol (2014) 0.78
Can ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy? Biomed Res Int (2014) 0.77
Population and target considerations for triple-negative breast cancer clinical trials. Biomark Med (2013) 0.76
Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy. Oncotarget (2017) 0.75
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) (2015) 0.75
Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer. A meta-analysis of randomized controlled trials. Saudi Med J (2017) 0.75
The Feasibility of Using Metacognitive Strategy Training to Improve Cognitive Performance and Neural Connectivity in Women with Chemotherapy-Induced Cognitive Impairment. Oncology (2016) 0.75
Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer. ISRN Oncol (2013) 0.75
Tumor Infiltrating Lymphocytes - The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast Cancer. J Carcinog Mutagen (2014) 0.75
Circulating tumor cell clusters-associated gene plakoglobin is a significant prognostic predictor in patients with breast cancer. Biomark Res (2017) 0.75
Optimal management of breast cancer in the elderly patient: current perspectives. Clin Interv Aging (2015) 0.75
Targets for Neoadjuvant Therapy - The Preferences of Patients with Early Breast Cancer. Geburtshilfe Frauenheilkd (2016) 0.75
Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study. BMC Cancer (2015) 0.75
Texture analysis on MR images helps predicting non-response to NAC in breast cancer. BMC Cancer (2015) 0.75
A Decision Aid for Women Considering Neoadjuvant Systemic Therapy for Operable Invasive Breast Cancer: Development and Protocol of a Phase II Evaluation Study (ANZ1301 DOMINO). JMIR Res Protoc (2016) 0.75
Association of PTP1B with Outcomes of Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy. Breast Cancer (Auckl) (2016) 0.75
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. Drugs (2017) 0.75
The accuracy of (18)F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review. Eur Radiol (2017) 0.75
Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol (2004) 6.47
Risk factors for anastomotic failure after total mesorectal excision of rectal cancer. Br J Surg (2005) 3.57
Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study. J Clin Oncol (2005) 2.77
Gastric cancer: epidemiology, pathology and treatment. Ann Oncol (2003) 2.53
Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys (2003) 2.38
Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. Br J Surg (2002) 2.13
Multicentre analysis of oncological and survival outcomes following anastomotic leakage after rectal cancer surgery. Br J Surg (2009) 2.00
Value of palliative resection in gastric cancer. Br J Surg (2002) 1.90
Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol (2002) 1.78
Urinary dysfunction after rectal cancer treatment is mainly caused by surgery. Br J Surg (2008) 1.75
Neoadjuvant chemotherapy for operable breast cancer. Br J Surg (2007) 1.55
Implementation of a short-stay programme after breast cancer surgery. Br J Surg (2010) 1.54
Sentinel lymph node biopsy in breast cancer. Ann Oncol (2002) 1.54
Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer (2012) 1.54
Leucocyte depletion of perioperative blood transfusion does not affect long-term survival and recurrence in patients with gastrointestinal cancer. Br J Surg (2009) 1.48
Variations in treatment policies and outcome for bladder cancer in the Netherlands. Eur J Surg Oncol (2010) 1.47
Origin of presacral local recurrence after rectal cancer treatment. Br J Surg (2010) 1.47
Quality indicators in breast cancer care. Eur J Cancer (2010) 1.46
[Clear-cut beneficial effect of breast cancer screening on the trend in breast-conserving surgery]. Ned Tijdschr Geneeskd (2002) 1.43
[The abdominal compartment syndrome]. Ned Tijdschr Geneeskd (2005) 1.41
Systematic review and meta-analysis of the volume-outcome relationship in pancreatic surgery. Br J Surg (2011) 1.40
Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer (2005) 1.40
Imaging for predicting the risk factors--the circumferential resection margin and nodal disease--of local recurrence in rectal cancer: a meta-analysis. Semin Ultrasound CT MR (2005) 1.39
Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol (2014) 1.39
[The treatment of patients with gastric carcinoma based on the results of Dutch studies]. Ned Tijdschr Geneeskd (2005) 1.39
Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol (2004) 1.39
Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). Breast Cancer Res Treat (2013) 1.39
Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer (2005) 1.38
Postoperative complications and survival of elderly breast cancer patients: a FOCUS study analysis. Breast Cancer Res Treat (2013) 1.31
Patient's needs and preferences in routine follow-up after treatment for breast cancer. Br J Cancer (2004) 1.30
Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients. Breast Cancer Res Treat (2010) 1.27
Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review. J Clin Oncol (2004) 1.27
Signet ring cell differentiation in mucinous colorectal carcinoma. J Pathol (2007) 1.25
Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial. Eur J Surg Oncol (2010) 1.19
A systematic review and meta-analysis of the volume-outcome relationship in the surgical treatment of breast cancer. Are breast cancer patients better of with a high volume provider? Eur J Surg Oncol (2010) 1.19
Volume and outcome in colorectal cancer surgery. Eur J Surg Oncol (2010) 1.17
Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer (2006) 1.16
Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. Br J Cancer (2004) 1.14
Gastric cancers in young and elderly patients show different genomic profiles. J Pathol (2007) 1.14
Clinical trial of combined radio- and fluorescence-guided sentinel lymph node biopsy in breast cancer. Br J Surg (2013) 1.14
Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J Cancer (2005) 1.10
Risk factors for sexual dysfunction after rectal cancer treatment. Eur J Cancer (2009) 1.08
The Dutch surgical colorectal audit. Eur J Surg Oncol (2013) 1.08
Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells. Cancer Immunol Immunother (2004) 1.08
Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol Immunol (2005) 1.08
Benefit from preoperative radiotherapy in rectal cancer treatment: disease-free patients' and oncologists' preferences. Br J Cancer (2007) 1.08
Differences in outcomes of oesophageal and gastric cancer surgery across Europe. Br J Surg (2012) 1.08
Adherence to treatment guidelines and survival in patients with early-stage breast cancer by age at diagnosis. Br J Surg (2012) 1.06
Transanal endoscopic microsurgery versus total mesorectal excision of T1 rectal adenocarcinomas with curative intention. Eur J Surg Oncol (2009) 1.05
Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis. Eur J Cancer (2002) 1.05
Treatment of liver metastases of colorectal cancer. Ann Oncol (2005) 1.04
The prognostic role of TGF-β signaling pathway in breast cancer patients. Ann Oncol (2012) 1.04
Near-infrared fluorescence imaging in patients undergoing pancreaticoduodenectomy. Eur Surg Res (2011) 1.03
Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. Br J Cancer (2006) 1.03
Metastatic lymph node ratio in stage III rectal cancer; prognostic significance in addition to the 7th edition of the TNM classification. Eur J Surg Oncol (2010) 1.03
Risk factors for faecal incontinence after rectal cancer treatment. Br J Surg (2007) 1.02
Results of a national survey among Dutch surgeons treating patients with colorectal carcinoma. Current opinion about follow-up, treatment of metastasis, and reasons to revise follow-up practice. Colorectal Dis (2007) 1.02
Epigenetic status of LINE-1 predicts clinical outcome in early-stage rectal cancer. Br J Cancer (2013) 1.01
Low Maruyama index surgery for gastric cancer: blinded reanalysis of the Dutch D1-D2 trial. World J Surg (2005) 1.01
MAL promoter hypermethylation as a novel prognostic marker in gastric cancer. Br J Cancer (2008) 1.00
Improving quality of cancer care through surgical audit. Eur J Surg Oncol (2010) 1.00
Modern multidisciplinary treatment of rectal cancer based on staging with magnetic resonance imaging leads to excellent local control, but distant control remains a challenge. Eur J Cancer (2013) 0.99
Impact of locoregional treatment on the early-stage breast cancer patients: a retrospective analysis. Eur J Cancer (2003) 0.99
The preferred treatment for young women with breast cancer--mastectomy versus breast conservation. Breast (2006) 0.98
Diabetes in relation to breast cancer relapse and all-cause mortality in elderly breast cancer patients: a FOCUS study analysis. Ann Oncol (2013) 0.98
Intraoperative near-infrared fluorescence imaging of colorectal metastases targeting integrin α(v)β(3) expression in a syngeneic rat model. Eur J Surg Oncol (2011) 0.97
Improved diagnosis and treatment of anastomotic leakage after colorectal surgery. Eur J Surg Oncol (2008) 0.97
Nerve sparing radical hysterectomy: latest developments and historical perspective. Crit Rev Oncol Hematol (2003) 0.97
Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries. Br J Surg (2010) 0.96
Patterns of lymphatic spread in rectal cancer. A topographical analysis on lymph node metastases. Eur J Cancer (2002) 0.96
Variation in treatment and outcome of patients with rectal cancer by region, hospital type and volume in the Netherlands. Eur J Surg Oncol (2010) 0.96
Results of European pooled analysis of IORT-containing multimodality treatment for locally advanced rectal cancer: adjuvant chemotherapy prevents local recurrence rather than distant metastases. Ann Oncol (2009) 0.95
Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study. Breast Cancer Res Treat (2012) 0.95
Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer. Br J Cancer (2011) 0.95
Expression of cell adhesion molecules and prognosis in breast cancer. Br J Surg (2012) 0.95
Prevention of seroma formation after axillary dissection in breast cancer: a systematic review. Eur J Surg Oncol (2011) 0.95
Cervical lymph node dissection for metastatic testicular cancer. Ann Surg Oncol (2010) 0.95
Combining process indicators to evaluate quality of care for surgical patients with colorectal cancer: are scores consistent with short-term outcome? BMJ Qual Saf (2012) 0.95
Professionals' opinion on follow-up in breast cancer patients; perceived purpose and influence of patients' risk factors. Eur J Surg Oncol (2011) 0.94
Nationwide decline in annual numbers of abdomino-perineal resections: effect of a successful national trial? Colorectal Dis (2003) 0.94
One hundred years of curative surgery for rectal cancer: 1908-2008. Eur J Surg Oncol (2008) 0.93
Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). Ann Oncol (2014) 0.93
The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a multistate model. Breast Cancer Res Treat (2009) 0.93
Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10 years in early stage breast cancer. Eur J Cancer (2012) 0.92
Localization of non-palpable breast cancer using a radiolabelled titanium seed. Br J Surg (2010) 0.92
How important is the opinion of significant others to cancer patients' adjuvant chemotherapy decision-making? Support Care Cancer (2006) 0.92
High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial. Eur J Surg Oncol (2011) 0.91
Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors. Crit Rev Oncol Hematol (2009) 0.91
Cost-effectiveness analysis of colorectal cancer treatments. Eur J Cancer (2002) 0.90
Dose optimization for near-infrared fluorescence sentinel lymph node mapping in patients with melanoma. Br J Dermatol (2013) 0.90
Surgery in metastatic breast cancer: patients with a favorable profile seem to have the most benefit from surgery. Eur J Surg Oncol (2011) 0.90
Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study. Psychooncology (2011) 0.90
Developments and quality assurance in rectal cancer surgery. Eur J Cancer (2002) 0.90
Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. Ann Oncol (2008) 0.89
The impact of the perception of treatment choice on satisfaction with treatment, experienced chemotherapy burden and current quality of life. Br J Cancer (2004) 0.89
Near-infrared fluorescence sentinel lymph node biopsy in vulvar cancer: a randomised comparison of lymphatic tracers. BJOG (2013) 0.89
[The multidisciplinary breast cancer care team: promoting better care]. Ned Tijdschr Geneeskd (2005) 0.89
Surgical treatment of early stage breast cancer in elderly: an international comparison. Breast Cancer Res Treat (2011) 0.89